Immunovant, Inc. (IMVT)
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Immunovant, Inc.
NASDAQ:IMVTHealthcare · Biotechnology
-1.59%$29.17
AH$29.17+0.00%vs close
Mkt Cap$6.03B
Float86.67M
O/S206.55M
Vol
$ Vol
RVOL
Inst Own54.1%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$505.61M
Total Assets$957.57M
Free Cash Flow-$407.32M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$72K
Total Equity$852.59M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in IMVT's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$957.57M
Liabilities$104.97M
Accounts Receivable$3.95M
Accounts Payable$7.54M
Inventory$0
PP&E (Net)$515K
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $409K | $0 | $0 | $0 | $0 | $0 | $21K | $0 | $0 |
| Gross Profit | -$409K | $0 | $0 | $0 | $0 | $0 | -$21K | $0 | $0 |
| Gross Margin | - | - | - | - | - | - | - | - | - |
| Research and Development | $456.66M | $360.92M | $212.93M | $160.26M | $101.81M | $68.6M | $47.93M | $25.73M | $135.26M |
| Selling, General, and Administrative | $76.24M | $77.23M | $57.28M | $48.02M | $54.23M | $39.51M | $11.73M | $448 | $1.48M |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $532.9M | $438.15M | $270.21M | $208.28M | $156.03M | $108.12M | $59.66M | $448 | $136.74M |
| Operating Income (EBIT) | -$532.9M | -$438.15M | -$270.21M | -$208.28M | -$156.03M | -$108.12M | -$59.68M | -$450 | -$136.74M |
| Operating Margin | - | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $12.48M | $0 | $0 | $625K | $0 | $0 |
| Interest Income | $25.33M | $24.73M | $24.95M | $7.58M | $0 | $0 | $625 | $0 | $0 |
| Other Income (Expense) | $27.51M | $25.2M | $11.44M | -$2.67M | -$781K | $328K | -$6.61M | $0 | $116 |
| Income Before Tax (EBT) | -$505.39M | -$412.95M | -$258.77M | -$210.95M | -$156.81M | -$107.79M | -$66.29M | -$448 | -$136.74M |
| Income Tax Expense | $215K | $891K | $567K | $9K | -$84K | -$358K | $97K | $0 | $0 |
| Net Income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$448 | -$136.74M |
| Net Income Margin | - | - | - | - | - | - | - | - | - |
| Supplementary Data | |||||||||
| EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -0.00 | -13.68 |
| Diluted EPS | -2.77 | -2.73 | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 | -0.00 | -13.67 |
| Weighted Average OS | 182.42M | 151.57M | 138.10M | 123.08M | 109.68M | 87.76M | 43.20M | 14.38M | 10.00M |
| EBITDA | -$504.98M | -$412.57M | -$258.54M | -$198.28M | -$156.69M | -$108.05M | -$65.64M | $10K | $0 |
| EBITDA Margin | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $325K | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $325K | $0 |
| Accounts Receivable | $3.95M | $2.51M | $5.5M | $885K | $12.86M | $1.14M | $3.04M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $42.76M | $51.18M | $24.9M | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $948.82M | $767.66M | $665.77M | $404.33M | $512.93M | $409.01M | $109.08M | $325K | $113K |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $515K | $942K | $595K | $1.5M | $2.63M | $3.48M | $65K | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $553K | $0 | $347K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $7.68M | $7.62M | $0 | $0 | $0 | $0 | $246K | $80K | $0 |
| Total Long-Term Assets | $8.75M | $8.56M | $942K | $1.5M | $2.63M | $3.48M | $311K | $80K | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $957.57M | $776.22M | $666.71M | $405.84M | $515.56M | $412.49M | $109.39M | $405K | $113K |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $7.54M | $17.66M | $7.16M | $1.35M | $18.63M | $2.43M | $1.19M | $0 | $1.14M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $3.19M | $300K | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$206 | $0 |
| Other Current Liabilities | $16.77M | $15.62M | $14.74M | $350K | $171K | $3.14M | $10.94M | -$206 | $0 |
| Total Current Liabilities | $104.42M | $68.78M | $48.61M | $43.3M | $44.52M | $18.77M | $15.32M | $380K | $1.61M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $553K | $0 | $347K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $553K | $0 | $347K | $47K | $1.22M | $2.24M | $0 | $300K | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$300K | $0 |
| Total Liabilities | $104.97M | $68.78M | $48.95M | $43.34M | $45.74M | $21.01M | $15.32M | $380K | $1.61M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $20K | $16K | $14K | $13K | $12K | $10K | $5K | $288 | $0 |
| Retained Earnings | -$1.75B | -$1.24B | -$825.68M | -$566.35M | -$355.39M | -$198.66M | -$91.23M | -$448 | $0 |
| Comprehensive Income & Other | $730K | $1.46M | $1.91M | $852K | $404K | -$298K | -$16K | $343K | -$1.5M |
| Other Stockholders' Equity | $2.6B | $1.95B | $1.44B | $928.83M | $825.2M | $590.13M | $185.29M | $25K | -$1.5M |
| Total Equity | $852.59M | $707.45M | $617.76M | $362.49M | $469.82M | $391.48M | $94.07M | $25K | -$1.5M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $957.57M | $776.22M | $666.71M | $405.84M | $515.56M | $412.49M | $109.39M | $405K | $113K |
| Supplementary Data | |||||||||
| Total Debt | $72K | $98K | $138K | $1.22M | $2.36M | $3.42M | $3.19M | $300K | $0 |
| Net Debt | -$902.04M | -$713.87M | -$635.23M | -$375.31M | -$491.45M | -$396.73M | -$97.38M | -$25K | $0 |
Cash Flow Statement
| Period | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 | 2018-03-31 |
| Operating Activities | |||||||||
| Net Income | -$505.61M | -$413.84M | -$259.34M | -$210.96M | -$156.73M | -$107.43M | -$66.39M | -$28.6M | -$136.74M |
| Depreciation & Amortization | $409K | $377K | $231K | $193K | $126K | $65K | $21K | $10K | $136.74M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $55.72M | $49.49M | $41.12M | $32.3M | $34.24M | $0 | $6.96M | $1.31M | $1.81M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | -$1.4M | $2.97M | -$4.56M | $12.22M | -$11.72M | $2.5M | -$83K | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$10.25M | $10.68M | $5.78M | -$17.12M | $16.25M | $1.25M | $967K | $0 | $0 |
| Other Working Capital | $53.72M | -$25.69M | $1.41M | -$5.95M | $10.61M | $818K | $3.92M | -$474K | $1.44M |
| Total Working Capital Change | $42.06M | -$12.03M | $2.63M | -$10.85M | $15.14M | $4.57M | $4.81M | -$474K | $1.44M |
| Other Non-Cash Items | $99K | $133K | $1.13M | $1.13M | $1.11M | $19.47M | $1.24M | -$792K | -$131.55M |
| Net Cash from Operating | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M | -$53.36M | -$28.55M | -$128.3M |
| Investing Activities | |||||||||
| Capital Expenditures | -$8K | -$759K | -$360K | -$197K | -$254K | -$210K | -$31K | -$52K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$8K | -$759K | -$360K | -$197K | -$254K | -$210K | -$31K | -$52K | $0 |
| Financing Activities | |||||||||
| Debt Repaid | - | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $596.26M | $450M | $472.75M | $70.5M | $129K | $386.3M | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$504K | $4.49M | -$318K | $385K | $200M | $0 | $109.07M | $35.58M | $128.3M |
| Net Cash from Financing | $595.76M | $454.49M | $472.43M | $70.89M | $200.13M | $383.11M | $146.97M | $35.58M | $128.3M |
| Forex Effect | -$299K | $747K | $993K | $220K | -$92K | $0 | $0 | $0 | $0 |
| Net Change in Cash | $188.14M | $78.61M | $258.83M | -$117.28M | $93.67M | $299.57M | $93.59M | $6.99M | $0 |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$407.31M | -$375.87M | -$214.23M | -$188.19M | -$106.11M | -$83.33M | -$53.36M | -$28.55M | -$128.3M |
| Capital Expenditure | -$8K | -$759K | -$360K | -$197K | -$254K | -$210K | -$31K | -$52K | $0 |
| Free Cash Flow | -$407.32M | -$376.63M | -$214.59M | -$188.39M | -$106.37M | -$83.54M | -$53.39M | -$28.6M | -$128.3M |
| Cash at Beginning | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $6.99M | $0 | $0 |
| Cash at End | $902.11M | $713.97M | $635.37M | $376.53M | $493.82M | $400.15M | $100.57M | $6.99M | $0 |